Background: Malnutrition amongst under-fives remains common in resource-poor countries and is resistant to current interventions. New opportunities have emerged to target “environmental enteric dysfunction” (EED) that refers to the abnormal gut structure and function that results from colonisation of the gut with pathogenic microbes and compromises nutrition and growth in early life. Although the gut microbiome may provide a defence against ingested gut pathogens through colonisation resistance, its development is adversely affected by multiple environmental factors. Dietary supplements of pro- or synbiotics may build the resilience of the gut microbiome against these environmental factors and boost colonisation resistance. We aim to assess whether dietary supplementation of newborns in rural Kenya with pro/synbiotics prevents or ameliorates EED and improves growth.Methods: Six hundred newborns less than 4 days old will be recruited from Homa Bay County Teaching and Referral Hospital, western Kenya. Newborns will be randomly allocated, stratified by HIV exposure, in a 1:1:1:1 ratio to one of 4 study arms to receive either of two synbiotics, a probiotic or no supplement. Supplements will be given daily for 10 days and then weekly until 6 months of age. Participants will be followed until the age of 2 years. The primary outcome is systemic inflammation at 6 months assessed by plasma alpha-1-acid glycoprotein. Secondary outcomes include biomarkers of gut health and growth, anthropometric indices, morbidity and mortality.Discussion: As dietary supplements with pro- or synbiotics may improve gut health and can be administered in early life, our findings may inform the package of interventions to prevent malnutrition and improve growth in Africa and similar low-resource settings.Trial registration: Pan African Clinical Trials Registry, Trial number: PACTR202003893276712. Date: 02/03/2020https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=9798
Background/Objectives: A contributory factor to childhood undernutrition is poor gut health occurring within the first 6–12 weeks of life despite exclusive breastfeeding. Pro/synbiotic administration may protect gut health. A qualitative study was conducted amongst mothers/carers and healthcare workers (HCWs) to explore their perceptions and the acceptability of pro/synbiotics administration in early life. Methods: This study was nested within a randomised, open, clinical trial of pro/synbiotics with 32 doses administered under supervision to infants between ages 0 and 5 months in western Kenya. Semi-structured interviews were conducted with 14 mothers/carers, 12 Peer Mothers and 7 healthcare workers (HCWs) selected by purposive critical and key informant sampling. Interviews were transcribed and analysed using a thematic coding framework. Results: The satisfaction with the pro/synbiotic administration was very high amongst all three groups. Commonly perceived benefits included protection from diseases, healthy growth of the infant and improved appetite. The main barriers were working mothers and other commitments making it difficult to stick to scheduled administration visits, adverse judgement and opinions in the community, and a lack of engagement from fathers. Insights were gained into different means of administering pro/synbiotics to young infants. Triangulation of the findings of the mothers/carers with HCWs showed that most identified motivations and challenges were similar. Conclusions: Pro/synbiotic administration was well accepted by the mothers/carers and HCWs and generally perceived to have health benefits. The administration of pro/synbiotics by the mothers/carers themselves to their infants may be feasible and overcome logistical challenges. Greater efforts to sensitise and engage fathers and communities would likely be critical for a community-based program.
Environmental enteric dysfunction (EED) in early life, caused by gut pathogen colonisation, contributes to chronic systemic inflammation (CSI) which impairs growth and organ development and increases non-communicable disease risk. Pro/synbiotics may prevent or ameliorate EED, and thereby reduce CSI, through boosting colonisation resistance against enteropathogens and provide other intestinal and immune benefits. We evaluated three pro/synbiotics consisting of live, multi-strain Bifidobacterium spp. and Lactobacillaceae in reducing CSI. In this open-label, randomised, four-arm, phase II trial, 600 healthy Kenyan newborns (1–3 days old, birthweight ≥2000g) were allocated 1:1:1:1, stratified by HIV exposure, to receive Labinic synbiotic, Lab4b synbiotic or Lab4b probiotic or no intervention daily for ten days, then weekly until six months. The primary outcome was CSI (plasma α1-acid glycoprotein > 1g/L) at six months with blinded laboratory assessments. At six months, CSI occurred in 60/138 (43%) controls versus 4/144 (3%; relative risk (RR) 0.06, 95% CI 0.02–0.17; p < 0.0001) infants in the Labinic synbiotic, 3/132 (2%; RR = 0.05, 0.02–0.16; P < 0.0001) in the Lab4b synbiotic, and 3/141 (2%; RR = 0.05, 0.02–0.15; P < 0.0001) in the Lab4b probiotic arm. Serious adverse events and mortality over 0–24 months were similar across study arms. Pro/synbiotics safely and markedly reduced CSI in this disadvantaged population, warranting investigation of health impacts.
Background: Undernutrition significantly contributes to infant mortality and underlies approximately 45% of global deaths in children under 5, making it one of the most concerning global child health issues. The PRObiotics and SYNbiotics in infants in Kenya (PROSYNK) trial is assessing whether supervised pro/synbiotic doses daily for the first 10 days and then weekly to age 6 months has a positive impact on gut health and thereby growth and nutrition. This study provides a cost analysis of the PROSYNK trial, estimates the costs of implementing the intervention, and offers feasability insights for delivering it to infants 0–5 months in rural Kenya. Methods: This provider perspective costing study used a combination of the ingredients approach, activity-based costing and microcosting. First, an empirical cost analysis of the PROSYNK trial was conducted by review of trial documentation and time and motion observations. Next, semistructured interviews with key informants informed a thematic analysis of implementation feasibility and the development of a theoretical programme structure, which formed the basis for estimating total economic programme costs. Results: The economic cost of delivering the full pro/synbiotics course under trial conditions was measured as US$701.61 per participant. Experience gained during PROSYNK and discussions with key informants suggest that it could be feasible for the Ministry of Health (MoH) to implement programmatic delivery of the pro/synbiotics, particularly through community-based delivery, without a cold chain and with pro/synbiotic administered directly into infants’ mouths. Incremental economic costs to the MoH of delivering the pro/synbiotic programmatically were estimated to be US$9.14 per infant per full course under the baseline scenario. Conclusion: Pro/synbiotic administration in early life may be feasible and bear similar costs to existing nutrition interventions. This study will provide policy makers and stakeholders with cost and feasibility insights to inform effective programmatic implementation in Kenya and similar settings.
The majority of the 2.4 million neonates (infants<28 days) who died in 2020 were born weighing <2500g i.e. low birth weight (LBW). In Africa, approximately 1 in 10 neonates are LBW. The majority of those who survive beyond the neonatal period are undernourished, have neuro-developmental impairment, or die before their second birthday. Unaddressed feeding difficulties contribute significantly to these adverse outcomes. This study assessed the feasibility and acceptability of using trained mother-to-mother peers (peer-mothers) to deliver breastfeeding support to mothers of LBW infants in healthcare facilities in rural Kenya. A mixed methods approach was employed, using structured observations, and pre- and post-intervention semi-structured interviews, with mothers, healthcare providers and peer-mothers. Six trained peer-mothers delivered the interventions to the mother-LBW infant pairs across eight healthcare facilities in Homa Bay County. Descriptive statistics were used to analyse the quantitative data and thematic analysis for the qualitative data. From September-November 2021, 23 mothers and 26 LBW infants were recruited and received the intervention. All infants were born in a hospital, the median age of the infants was 1 day (Interquartile range, IQR 1,3), birth weight 2100g (IQR 1900, 2260) and recorded gestation 34 weeks (IQR 34,36). Although all mothers looked well, 4 (17%) showed no signs of bonding with their infant. One infant was too weak to suckle and was referred to healthcare providers. Key themes were challenges with infant feeding decision-making among mothers of LBW infants, community misconceptions of recommended infant feeding practices for LBW infants, and the integral role of peer-mothers in maternity units. Facility-based, breastfeeding peer support for LBW infants was feasible and acceptable in the context of resource constraints. It could improve uptake of appropriate infant feeding practices among these vulnerable infants and enhance their post-discharge survival and growth outcomes. This strategy warrants further evaluation in a larger study.
Background: The COVID-19 pandemic presented unprecedented challenges to the conduct of non- pandemic research. The pandemic disrupted regulatory processes, strained health systems, and necessitated ethical recalibrations. This paper reports a retrospective study of the experience of conducting one clinical study of a non-pandemic related trial in western Kenya, conducted between October 2020 and January 2024. The original study documents were reviewed to identify lessons learned, particularly those relevant to ethical and regulatory aspects of conducting non-pandemic research during a pandemic. Methods: A retrospective documentary case analysis was conducted using archived ethics and regulatory submissions, study progress reports, meeting minutes, and relevant peer-reviewed literature. A framework analysis approach guided thematic coding, supported by independent dual review to ensure reliability (Cohen’s Kappa ≥0.6). Results: Public health restrictions during the third pandemic wave, particularly at the main recruitment site, compounded delays. Adaptive measures included reduced physical contact, use of satellite recruitment centers, community engagement with Traditional Birth Attendants, and remote monitoring via digital platforms. Parallel submission to both the Ethics Review Committee and the Regulatory Authority notably expedited the overall turnaround time for approval of protocol amendments. Despite these challenges, the study achieved an impressive 91% follow-up completion rate, with 96% of scheduled home visits successfully carried out. Conclusion: This case study highlights how flexible, community-informed, and ethically responsive research practices can sustain clinical trials under adverse conditions. Strong stakeholder collaboration, open communication, and proactive risk mitigation were essential to maintaining study integrity and protecting participant welfare. These findings underscore the need for future research designs to embed contingency planning, community partnerships, and regulatory adaptability to ensure continuity and resilience for research conducted during public health emergencies.